<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31719004</article-id><article-id pub-id-type="pmc">6852459</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2019-0285</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Cardiovascular disease: The Brazilian research
contribution</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4082-5758</contrib-id><name><surname>Krauskopf</surname><given-names>Erwin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/><role>PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Universidad Andr&#x000e9;s Bello - Facultad de Ciencias de la Vida,
Santiago, Chile.</aff><aff id="aff2">
<label>2</label>Fundaci&#x000f3;n Ciencia Para la Vida, Santiago, Chile.</aff><author-notes><corresp id="c1">E-mail: <email>erwin.krauskopf@unab.cl</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2019</year></pub-date><volume>34</volume><issue>5</issue><fpage>VI</fpage><lpage>IX</lpage><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions></article-meta></front><body><p>Cardiovascular disease is the leading cause of death around the world. According to a
study from the World Economic Forum, the economic burden of this disease to society
reached US$ 863 billion in 2010, with an estimation to rise by 22% to US$ 1,044 in
2030<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Likewise, recent
studies have shown that in Brazil ischemic heart disease and stroke have been the main
cause of death since the end of the 1960s, costing a total of R$ 56.2 billion just in
2015<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Due to Brazil&#x02019;s large size, its 27 states have developed
unevenly, so states located in the south and southeast regions of the country are more
developed and have the best infrastructure<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Hence, such differences ought to be considered when allocating
resources efficiently to improve healthcare among the population. It is imperative to
seek knowledge through locally-based research as its outcomes may be used as a tool to
instruct policy makers, regional-level physicians, health professionals and the general
population<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>To establish the Brazilian contribution to cardiovascular disease research, the Scival
platform (<ext-link ext-link-type="uri" xlink:href="http://www.scival.com">www.scival.com</ext-link>) was used, which analyzes data from several sources such
as Scopus and ScienceDirect. In the case of patent article citations, data emanate from
European Patent Office, Intellectual Property Office, Japan Patent Office, United States
Patent and Trademark Office and the World Intellectual Property Organization. A query
was made to retrieve data from Brazil which had been published within the most recent
5-year period (2014-2018) in the field of &#x0201c;Cardiology and Cardiovascular Medicine&#x0201d;. One
of the key features of Scival is that it disaggregates each field into specific research
topics. As approximately 96,000 specific research topics have been defined, topic
clusters are formed by aggregating topics with similar research interest, creating a
broader area of research<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. It is
important to note that a publication can belong to only one topic, consequently, to one
topic cluster.</p><p>The indicators used for this analysis were the following:</p><p>
<list list-type="bullet"><list-item><p>Scholarly output: The number of documents published within the 5-year period
in the topic cluster.</p></list-item><list-item><p>Growth (%): This indicator represents the increase or decrease of published
documents within the specific topic cluster in the 5-year period.</p></list-item><list-item><p>International collaboration (%): The proportion of published documents
authored by researchers from Brazil and another countries.</p></list-item><list-item><p>Field-Weighted Citation Impact (FWCI): Indicator that refers to citations
received in the year of publication plus the following 3 years. FWCI of 1.00
means that the publications have been cited at world average for similar
publications. Thus, a score of 1.17 indicates that the outputs have been
cited 17% more than expected. Contrarily, a FWCI of 0.77 means 23% less
cited than the world average.</p></list-item><list-item><p>Patent-cited scholarly output: The count of scholarly outputs published by
the country that have been cited in patents.</p></list-item></list>
</p><p>As <xref rid="t1" ref-type="table">Table 1</xref> reveals, the field of &#x0201c;Cardiology and
Cardiovascular Medicine&#x0201d; in Brazil is constituted by 47 topic clusters, ordered
according to the number of papers published within the 5-year period. The most prolific
topic was &#x0201c;Percutaneous coronary intervention; Patients; Myocardial infarction&#x0201d;, with
584 papers, of which 49.3% were the product of an international collaboration. While its
growth has diminished slightly over the 5-year period, its FWCI score denotes that these
papers have been cited 99% more than expected. In fact, the six most prolific topic
cluster exhibits an FWCI &#x0003e;1, revealing the quality of the work published.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Topic clusters associated to the field of cardiovascular disease.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Topic cluster</th><th align="center" rowspan="1" colspan="1">Scholarly output</th><th align="center" rowspan="1" colspan="1">Growth (%)</th><th align="center" rowspan="1" colspan="1">International collaboration (%)</th><th align="center" rowspan="1" colspan="1">Field-Weighted Citation Impact</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Percutaneous Coronary Intervention; Patients; Myocardial
Infarction</td><td align="center" rowspan="1" colspan="1">584</td><td align="center" rowspan="1" colspan="1">-1.7</td><td align="center" rowspan="1" colspan="1">49.3</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial Fibrillation; Patients; Catheter Ablation</td><td align="center" rowspan="1" colspan="1">570</td><td align="center" rowspan="1" colspan="1">54.3</td><td align="center" rowspan="1" colspan="1">48.8</td><td align="center" rowspan="1" colspan="1">1.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol; Lipids; Atherosclerosis</td><td align="center" rowspan="1" colspan="1">492</td><td align="center" rowspan="1" colspan="1">15.8</td><td align="center" rowspan="1" colspan="1">35.8</td><td align="center" rowspan="1" colspan="1">2.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis; Acute Kidney Injury; Patients</td><td align="center" rowspan="1" colspan="1">483</td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">32.7</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Anticoagulants; Patients; Venous Thromboembolism</td><td align="center" rowspan="1" colspan="1">472</td><td align="center" rowspan="1" colspan="1">28.1</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">1.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Rate; Blood Pressure; Patients</td><td align="center" rowspan="1" colspan="1">412</td><td align="center" rowspan="1" colspan="1">27.6</td><td align="center" rowspan="1" colspan="1">40.3</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Wounds and Injuries; Pressure Ulcer; Bandages</td><td align="center" rowspan="1" colspan="1">385</td><td align="center" rowspan="1" colspan="1">60.6</td><td align="center" rowspan="1" colspan="1">12.7</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Renin-Angiotensin System; Peptidyl-Dipeptidase A;
Angiotensins</td><td align="center" rowspan="1" colspan="1">348</td><td align="center" rowspan="1" colspan="1">-7.4</td><td align="center" rowspan="1" colspan="1">36.8</td><td align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension; Blood Pressure; Patients</td><td align="center" rowspan="1" colspan="1">337</td><td align="center" rowspan="1" colspan="1">6.2</td><td align="center" rowspan="1" colspan="1">35.6</td><td align="center" rowspan="1" colspan="1">2.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke; Patients; Cerebral Hemorrhage</td><td align="center" rowspan="1" colspan="1">303</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">30.7</td><td align="center" rowspan="1" colspan="1">1.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Failure; Patients; Brain Natriuretic Peptide</td><td align="center" rowspan="1" colspan="1">301</td><td align="center" rowspan="1" colspan="1">-6.5</td><td align="center" rowspan="1" colspan="1">36.2</td><td align="center" rowspan="1" colspan="1">1.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary Artery Disease; Patients; Echocardiography</td><td align="center" rowspan="1" colspan="1">264</td><td align="center" rowspan="1" colspan="1">19.3</td><td align="center" rowspan="1" colspan="1">45.8</td><td align="center" rowspan="1" colspan="1">1.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic Valve; Mitral Valve; Aortic Valve Stenosis</td><td align="center" rowspan="1" colspan="1">253</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">37.2</td><td align="center" rowspan="1" colspan="1">1.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic Preconditioning; Reperfusion Injury; Ischemic
Postconditioning</td><td align="center" rowspan="1" colspan="1">221</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">13.6</td><td align="center" rowspan="1" colspan="1">1.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Diseases; Patients; Congenital Heart Defects</td><td align="center" rowspan="1" colspan="1">211</td><td align="center" rowspan="1" colspan="1">-30.4</td><td align="center" rowspan="1" colspan="1">21.8</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal Aortic Aneurysm; Aneurysm; Dissection</td><td align="center" rowspan="1" colspan="1">191</td><td align="center" rowspan="1" colspan="1">-2.6</td><td align="center" rowspan="1" colspan="1">22.0</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Vasodilation; Endothelium; Dilatation</td><td align="center" rowspan="1" colspan="1">171</td><td align="center" rowspan="1" colspan="1">51.2</td><td align="center" rowspan="1" colspan="1">16.4</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Catheters; Renal Dialysis; Central Venous Catheters</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">96.3</td><td align="center" rowspan="1" colspan="1">13.1</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumothorax; Lung; Pleural Effusion</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">11.6</td><td align="center" rowspan="1" colspan="1">22.5</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary Hypertension; Pulmonary Artery; Patients</td><td align="center" rowspan="1" colspan="1">136</td><td align="center" rowspan="1" colspan="1">61.2</td><td align="center" rowspan="1" colspan="1">47.4</td><td align="center" rowspan="1" colspan="1">1.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Rehabilitation; Depression; Patients</td><td align="center" rowspan="1" colspan="1">135</td><td align="center" rowspan="1" colspan="1">63.2</td><td align="center" rowspan="1" colspan="1">38.5</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Arrest; Cardiopulmonary Resuscitation;
Out-Of-Hospital Cardiac Arrest</td><td align="center" rowspan="1" colspan="1">115</td><td align="center" rowspan="1" colspan="1">23.6</td><td align="center" rowspan="1" colspan="1">41.2</td><td align="center" rowspan="1" colspan="1">1.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral Arterial Disease; Ischemia; Extremities</td><td align="center" rowspan="1" colspan="1">113</td><td align="center" rowspan="1" colspan="1">-28.9</td><td align="center" rowspan="1" colspan="1">21.2</td><td align="center" rowspan="1" colspan="1">1.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular Stiffness; Pulse Wave Analysis; Blood
Pressure</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">11.4</td><td align="center" rowspan="1" colspan="1">33.0</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Matrix Metalloproteinases; Matrix Metalloproteinase 9;
Metalloproteases</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">-22.8</td><td align="center" rowspan="1" colspan="1">33.0</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium; Calcium Signaling; Ion Channels</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">-6.1</td><td align="center" rowspan="1" colspan="1">53.6</td><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Uric Acid; Gout; Hyperuricemia</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">20.7</td><td align="center" rowspan="1" colspan="1">33.7</td><td align="center" rowspan="1" colspan="1">1.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphedema; Breast Neoplasms; Chylothorax</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">15.6</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Enterovirus; Poliomyelitis; Myocarditis</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">30.5</td><td align="center" rowspan="1" colspan="1">43.2</td><td align="center" rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis; Aneurysm; Patients</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">22.2</td><td align="center" rowspan="1" colspan="1">18.5</td><td align="center" rowspan="1" colspan="1">1.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart-Assist Devices; Extracorporeal Membrane Oxygenation;
Patients</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">-10.8</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythrocyte Indices; Neutrophils; Lymphocytes</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">-25.8</td><td align="center" rowspan="1" colspan="1">10.8</td><td align="center" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertrophic Cardiomyopathy; Myosins; Cardiomyopathies</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">21.2</td><td align="center" rowspan="1" colspan="1">32.8</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Anthracyclines; Doxorubicin; Neoplasms</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">30.7</td><td align="center" rowspan="1" colspan="1">28.1</td><td align="center" rowspan="1" colspan="1">1.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Sarcoidosis; Granuloma; Patients</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">119.4</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Trachea; Thoracic Aorta; Bronchoscopy</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">47.7</td><td align="center" rowspan="1" colspan="1">16.0</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemia; Patients; Superior Mesenteric Artery</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">-0.4</td><td align="center" rowspan="1" colspan="1">17.4</td><td align="center" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary Vessels; Pulmonary Artery; Fistula</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">-1.5</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Neoplasms; Myxoma; Echocardiography</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">131.2</td><td align="center" rowspan="1" colspan="1">26.3</td><td align="center" rowspan="1" colspan="1">1.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythrocytes; Contrast Media; Blood</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">-24</td><td align="center" rowspan="1" colspan="1">21.6</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal Artery; Renal Artery Obstruction; Hypertension</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">25.7</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyponatremia; Sodium; Hyperkalemia</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">132.7</td><td align="center" rowspan="1" colspan="1">34.4</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Inferior Vena Cava; Renal Veins; Syndrome</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">177.5</td><td align="center" rowspan="1" colspan="1">9.4</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart; Acoustic Waves; Cardiology</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">-13.4</td><td align="center" rowspan="1" colspan="1">26.7</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pregnancy; Dissection; Coronary Vessels</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">-72.4</td><td align="center" rowspan="1" colspan="1">14.8</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Pericarditis; Pericardial Effusion; Constrictive
Pericarditis</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">76.1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Takotsubo Cardiomyopathy; Patients;
Electrocardiography</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">-7.5</td><td align="center" rowspan="1" colspan="1">35.3</td><td align="center" rowspan="1" colspan="1">0.66</td></tr></tbody></table></table-wrap><p>Another important aspect to consider is the impact of the Brazilian papers in patent
generation. As Collins and Wyatt<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>
stated, the main characteristic of papers cited by patents must be in a rapidly
developing field with a high scientific content. To understand the real value of these
papers, 509 US patents issued from 1987 to 2003 cited 273 Chilean papers from several
disciplines<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. In this regard,
<xref rid="t2" ref-type="table">Table 2</xref> summarizes the Brazilian papers cited
in 16 patents issued from 2014 to 2018.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Brazilian papers cited in patents.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="60%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Title</th><th align="center" rowspan="1" colspan="1">Year</th><th align="center" rowspan="1" colspan="1">Source</th><th align="center" rowspan="1" colspan="1">Volume</th><th align="center" rowspan="1" colspan="1">Pages</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pleural subxyphoid drain confers better pulmonary function
and clinical outcomes in chronic obstructive pulmonary disease after
off-pump coronary artery bypass grafting: A randomized controlled
trial</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Brazilian Journal of Cardiovascular Surgery</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">588-594</td></tr><tr><td align="left" rowspan="1" colspan="1">Butyrate impairs atherogenesis by reducing plaque
inflammation and vulnerability and decreasing NF&#x003ba;B
activation</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Nutrition, Metabolism and Cardiovascular Diseases</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">606-613</td></tr><tr><td align="left" rowspan="1" colspan="1">Vorapaxar in acute coronary syndrome patients undergoing
coronary artery bypass graft surgery: Subgroup analysis from the TRACER
trial (Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome)</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Journal of the American College of Cardiology</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">1048-1057</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin-associated muscle symptoms: impact on statin therapy
- European Atherosclerosis Society Consensus Panel Statement on
Assessment, Aetiology and Management</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">European Heart Journal</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">1012-1022</td></tr><tr><td align="left" rowspan="1" colspan="1">Management of pulmonary arterial hypertension</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Journal of the American College of Cardiology</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">1976-1997</td></tr><tr><td align="left" rowspan="1" colspan="1">Simplified Method for Vagal Effect Evaluation in Cardiac
Ablation and Electrophysiological Procedures</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">JACC: Clinical Electrophysiology</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">451-460</td></tr><tr><td align="left" rowspan="1" colspan="1">2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement
on catheter and surgical ablation of atrial fibrillation: Executive
summary</td><td align="center" rowspan="1" colspan="1">2017</td><td align="center" rowspan="1" colspan="1">Heart Rhythm</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">e445-e494</td></tr><tr><td align="left" rowspan="1" colspan="1">Targeting PCSK9 for therapeutic gains: Have we addressed
all the concerns?</td><td align="center" rowspan="1" colspan="1">2016</td><td align="center" rowspan="1" colspan="1">Atherosclerosis</td><td align="center" rowspan="1" colspan="1">248</td><td align="center" rowspan="1" colspan="1">62-75</td></tr><tr><td align="left" rowspan="1" colspan="1">Ticagrelor for Prevention of Ischemic Events After
Myocardial Infarction in Patients with Peripheral Artery Disease</td><td align="center" rowspan="1" colspan="1">2016</td><td align="center" rowspan="1" colspan="1">Journal of the American College of Cardiology</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">2719-2728</td></tr><tr><td align="left" rowspan="1" colspan="1">Association of endothelial dysfunction with cardiovascular
risk factors and new-onset diabetes mellitus in patients with
hypertension</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Journal of Clinical Hypertension</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">935-941</td></tr></tbody></table></table-wrap><p>Undoubtedly, research developed by Brazilian investigators in topics related to
cardiovascular disease has proven valuable, not only for the academic community, but
also for the industry. I believe now is the time to make this research useful for policy
makers to influence their assessments.</p></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>DE</given-names></name><name><surname>Cafiero</surname><given-names>ET</given-names></name><name><surname>Jan&#x000e9;-Llopis</surname><given-names>E</given-names></name><name><surname>Abrahams-Gessel</surname><given-names>S</given-names></name><name><surname>Bloom</surname><given-names>LR</given-names></name><name><surname>Fathima</surname><given-names>S</given-names></name><etal/></person-group><source>The global economic burden of noncommunicable diseases</source><comment>[Internet]</comment><year>2011</year><publisher-loc>Geneva (CH)</publisher-loc><publisher-name>World Economic Forum</publisher-name><date-in-citation content-type="access-date">2019 Sep 20</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf">http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf</ext-link></comment></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2016 Brazil Collaborators</collab></person-group><article-title>Burden of disease in Brazil, 1990-2016: a systematic subnational
analysis for the global burden of disease study 2016</article-title><source>Lancet</source><year>2018</year><volume>392</volume><issue>10149</issue><fpage>760</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31221-2</pub-id><pub-id pub-id-type="pmid">30037735</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>B</given-names></name><name><surname>Pezzullo</surname><given-names>L</given-names></name><name><surname>Verdian</surname><given-names>L</given-names></name><name><surname>Tomlinson</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>A</given-names></name><name><surname>Bacal</surname><given-names>F</given-names></name></person-group><article-title>The economic burden of heart conditions in Brazil</article-title><source>Arq Bras Cardiol</source><year>2018</year><volume>111</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.5935/abc.20180104</pub-id><pub-id pub-id-type="pmid">30110042</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behague</surname><given-names>D</given-names></name><name><surname>Tawiah</surname><given-names>C</given-names></name><name><surname>Rosato</surname><given-names>M</given-names></name><name><surname>Some</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name></person-group><article-title>Evidence-based policy-making: the implications of
globally-applicable research for context-specific problem-solving in
developing countries</article-title><source>Soc Sci Med</source><year>2009</year><volume>69</volume><issue>10</issue><fpage>1539</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2009.08.006</pub-id><pub-id pub-id-type="pmid">19781839</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Scival</collab></person-group><source>Scival user guide</source><publisher-loc>Oxford (UK)</publisher-loc><publisher-name>Elsevier</publisher-name><year>c2019</year><fpage>106</fpage><lpage>106</lpage></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Wyatt</surname><given-names>S</given-names></name></person-group><article-title>Citations in patents to the basic research
literature</article-title><source>Res Pol</source><year>1988</year><volume>17</volume><issue>2</issue><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/0048-7333(88)90022-4</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauskopf</surname><given-names>M</given-names></name><name><surname>Krauskopf</surname><given-names>E</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>B</given-names></name></person-group><article-title>Low awareness of the link between science and innovation affects
public policies in developing countries: the Chilean case</article-title><source>Scientometrics</source><year>2007</year><volume>72</volume><issue>1</issue><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1007/s11192-007-1737-5</pub-id></element-citation></ref></ref-list></back></article>